Form 4: Astrana Health Director Weili Dai Reports Acquisition of Restricted Stock

Director Weili Dai reports acquisition of 3,564 shares of restricted Astrana Health stock, along with adjustments to existing holdings.

Summary

• On August 13, 2024, Weili Dai, a director of Astrana Health, Inc. (ASTH), reported acquiring 3,564 shares of common stock.
• These shares were granted as restricted stock under the company's 2024 Equity Incentive Plan.
• The restricted shares will vest on the earlier of August 13, 2025, or the date of the Issuer's 2025 annual meeting of stockholders.
• Following the transaction, Dai's total beneficial ownership includes 7,214 shares, including 3,650 shares vesting on December 9, 2024, and 3,564 shares vesting later.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard insider transaction related to equity compensation, which is generally viewed as a positive sign of alignment between management and shareholders.

Positives

• The acquisition of restricted stock aligns the director's interests with the long-term performance of the company.
• The vesting schedule encourages continued service and contribution to Astrana Health.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the restricted stock.

Industry Context

This filing is a routine disclosure related to insider transactions, common in publicly traded companies. It reflects standard practices for equity compensation and alignment of interests between management and shareholders.

Comparison to Industry Standards

• Equity compensation is a common practice among publicly traded companies to incentivize and retain key personnel.
• Vesting schedules, like the one described, are standard in the industry to ensure continued service.
• Companies like UnitedHealth Group (UNH) and CVS Health (CVS) also utilize equity incentive plans for their executives and directors.

Stakeholder Impact

• The acquisition of restricted stock by a director can positively influence shareholder confidence.
• It aligns the director's interests with the company's performance, potentially benefiting shareholders.

Key Dates